Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Relapsed Acute Myeloid Leukemia Overview | 17 | 1 |
| Therapeutics Development | 18 | 2 |
| Pipeline Products for Relapsed Acute Myeloid Leukemia Overview | 18 | 1 |
| Pipeline Products for Relapsed Acute Myeloid Leukemia Comparative Analysis | 19 | 1 |
| Relapsed Acute Myeloid Leukemia Therapeutics under Development by Companies | 20 | 4 |
| Relapsed Acute Myeloid Leukemia Therapeutics under Investigation by Universities/Institutes | 24 | 1 |
| Relapsed Acute Myeloid Leukemia Pipeline Products Glance | 25 | 3 |
| Late Stage Products | 25 | 1 |
| Clinical Stage Products | 26 | 1 |
| Early Stage Products | 27 | 1 |
| Relapsed Acute Myeloid Leukemia Products under Development by Companies | 28 | 5 |
| Relapsed Acute Myeloid Leukemia Products under Investigation by Universities/Institutes | 33 | 1 |
| Relapsed Acute Myeloid Leukemia Companies Involved in Therapeutics Development | 34 | 57 |
| 4SC AG | 34 | 1 |
| AbbVie Inc | 35 | 1 |
| Actinium Pharmaceuticals, Inc. | 36 | 1 |
| ADC Therapeutics Sarl | 37 | 1 |
| Aeglea BioTherapeutics, Inc. | 38 | 1 |
| Agios Pharmaceuticals, Inc. | 39 | 1 |
| Aileron Therapeutics, Inc. | 40 | 1 |
| Amgen Inc. | 41 | 1 |
| Arog Pharmaceuticals, Inc. | 42 | 1 |
| Array BioPharma Inc. | 43 | 1 |
| Astellas Pharma Inc. | 44 | 1 |
| AstraZeneca Plc | 45 | 1 |
| AVEO Pharmaceuticals, Inc. | 46 | 1 |
| Bellicum Pharmaceuticals, Inc. | 47 | 1 |
| Bio-Cancer Treatment International Limited | 48 | 1 |
| BioLineRx, Ltd. | 49 | 1 |
| BioSight Ltd. | 50 | 1 |
| Boehringer Ingelheim GmbH | 51 | 1 |
| Boston Biomedical, Inc. | 52 | 1 |
| Bristol-Myers Squibb Company | 53 | 1 |
| Calithera Biosciences, Inc. | 54 | 1 |
| Celgene Corporation | 55 | 1 |
| Cornerstone Pharmaceuticals, Inc. | 56 | 1 |
| CSPC Pharmaceutical Group Limited | 57 | 1 |
| CTI BioPharma Corp. | 58 | 1 |
| Daiichi Sankyo Company, Limited | 59 | 1 |
| Eisai Co., Ltd. | 60 | 1 |
| Eli Lilly and Company | 61 | 1 |
| EpiZyme, Inc. | 62 | 1 |
| Exelixis, Inc. | 63 | 1 |
| F. Hoffmann-La Roche Ltd. | 64 | 1 |
| FLX Bio, Inc. | 65 | 1 |
| FORMA Therapeutics Inc | 66 | 1 |
| Fujifilm Corporation | 67 | 1 |
| GlaxoSmithKline Plc | 68 | 1 |
| GlycoMimetics, Inc. | 69 | 1 |
| Igenica Biotherapeutics, Inc. | 70 | 1 |
| Incyte Corporation | 71 | 1 |
| JW Pharmaceutical Corporation | 72 | 1 |
| Karyopharm Therapeutics, Inc. | 73 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 74 | 1 |
| MacroGenics, Inc. | 75 | 1 |
| Merck &Co., Inc. | 76 | 1 |
| Millennium Pharmaceuticals Inc | 77 | 1 |
| NantKwest, Inc. | 78 | 1 |
| Novartis AG | 79 | 1 |
| Oxford BioTherapeutics Ltd | 80 | 1 |
| Pfizer Inc. | 81 | 1 |
| Pharma Mar, S.A. | 82 | 1 |
| Polaris Pharmaceuticals, Inc. | 83 | 1 |
| Seattle Genetics, Inc. | 84 | 1 |
| Sunesis Pharmaceuticals, Inc. | 85 | 1 |
| TaiGen Biotechnology Co., Ltd. | 86 | 1 |
| Teva Pharmaceutical Industries Ltd. | 87 | 1 |
| Tolero Pharmaceuticals, Inc. | 88 | 1 |
| VioQuest Pharmaceuticals, Inc. | 89 | 1 |
| ZIOPHARM Oncology, Inc. | 90 | 1 |
| Relapsed Acute Myeloid Leukemia Therapeutics Assessment | 91 | 20 |
| Assessment by Monotherapy Products | 91 | 1 |
| Assessment by Combination Products | 92 | 1 |
| Assessment by Target | 93 | 7 |
| Assessment by Mechanism of Action | 100 | 7 |
| Assessment by Route of Administration | 107 | 2 |
| Assessment by Molecule Type | 109 | 2 |
| Drug Profiles | 111 | 314 |
| 4SC-202 Drug Profile | 111 | 2 |
| Actimab-A Drug Profile | 113 | 7 |
| ADCT-301 Drug Profile | 120 | 1 |
| AEB-1102 Drug Profile | 121 | 2 |
| AG-120 Drug Profile | 123 | 4 |
| AG-881 Drug Profile | 127 | 1 |
| ALRN-6924 Drug Profile | 128 | 2 |
| alvocidib hydrochloride Drug Profile | 130 | 3 |
| AMG-232 Drug Profile | 133 | 1 |
| AMG-330 Drug Profile | 134 | 1 |
| aNK Program Drug Profile | 135 | 2 |
| APTA-16 Drug Profile | 137 | 1 |
| arsenic trioxide Drug Profile | 138 | 2 |
| atezolizumab Drug Profile | 140 | 14 |
| AZD-1775 Drug Profile | 154 | 3 |
| BCT-100 Drug Profile | 157 | 2 |
| BI-836858 Drug Profile | 159 | 1 |
| binimetinib Drug Profile | 160 | 7 |
| BL-8040 Drug Profile | 167 | 10 |
| bortezomib Drug Profile | 177 | 8 |
| BPX-701 Drug Profile | 185 | 1 |
| BST-236 Drug Profile | 186 | 1 |
| buparlisib hydrochloride Drug Profile | 187 | 5 |
| burixafor Drug Profile | 192 | 1 |
| cabozantinib s-malate Drug Profile | 193 | 18 |
| CB-839 Drug Profile | 211 | 7 |
| CC-90009 Drug Profile | 218 | 1 |
| Cellular Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome Drug Profile | 219 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 220 | 1 |
| Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia Drug Profile | 221 | 1 |
| Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia Drug Profile | 222 | 1 |
| Cellular Immunotherapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia Drug Profile | 223 | 1 |
| Cellular Immunotherapy to Target Tumor Associated Antigen for Hematopoietic Malignancies Drug Profile | 224 | 1 |
| Cellular Immunotherapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology Drug Profile | 225 | 1 |
| Cellular Immunotherapy to Target WT1 for Acute Myeloid Leukemia Drug Profile | 226 | 1 |
| Cellular Immunotherapy to Target WT1 for Acute Myleoid Leukemia and Infectious Disease Drug Profile | 227 | 1 |
| CPI-613 Drug Profile | 228 | 5 |
| crenolanib besylate Drug Profile | 233 | 3 |
| CWP-291 Drug Profile | 236 | 1 |
| DFP-10917 Drug Profile | 237 | 1 |
| DS-3032 Drug Profile | 238 | 1 |
| E-6201 Drug Profile | 239 | 2 |
| eltrombopag olamine Drug Profile | 241 | 5 |
| enasidenib mesylate Drug Profile | 246 | 5 |
| erlotinib hydrochloride Drug Profile | 251 | 4 |
| FF-10501 Drug Profile | 255 | 1 |
| ficlatuzumab Drug Profile | 256 | 3 |
| FLX-925 Drug Profile | 259 | 1 |
| FT-1101 Drug Profile | 260 | 1 |
| gedatolisib Drug Profile | 261 | 2 |
| gilteritinib fumarate Drug Profile | 263 | 2 |
| GMI-1271 Drug Profile | 265 | 5 |
| GO-2032c Drug Profile | 270 | 2 |
| GSK-2879552 Drug Profile | 272 | 1 |
| GSK-525762 Drug Profile | 273 | 1 |
| Hu8F4 Drug Profile | 274 | 1 |
| HXR-9 Drug Profile | 275 | 1 |
| IGN-523 Drug Profile | 276 | 2 |
| imatinib mesylate Drug Profile | 278 | 3 |
| indisulam Drug Profile | 281 | 1 |
| Iomab-B Drug Profile | 282 | 5 |
| KHK-2823 Drug Profile | 287 | 1 |
| lenalidomide Drug Profile | 288 | 14 |
| lirilumab Drug Profile | 302 | 4 |
| lurbinectedin Drug Profile | 306 | 7 |
| LY-2510924 Drug Profile | 313 | 2 |
| MB-102 Drug Profile | 315 | 1 |
| MGD-006 Drug Profile | 316 | 2 |
| MK-2206 Drug Profile | 318 | 3 |
| napabucasin Drug Profile | 321 | 6 |
| Oshadi D + Oshadi R Drug Profile | 327 | 1 |
| OX-001 Drug Profile | 328 | 1 |
| pegargiminase Drug Profile | 329 | 7 |
| PIM-447 Drug Profile | 336 | 1 |
| pinometostat Drug Profile | 337 | 4 |
| PLX-51107 Drug Profile | 341 | 1 |
| quizartinib dihydrochloride Drug Profile | 342 | 8 |
| RG-6146 Drug Profile | 350 | 1 |
| ruxolitinib phosphate Drug Profile | 351 | 13 |
| S-055746 Drug Profile | 364 | 1 |
| selinexor Drug Profile | 365 | 18 |
| SGNCD-123A Drug Profile | 383 | 1 |
| SKLB-1028 Drug Profile | 384 | 1 |
| TAK-659 Drug Profile | 385 | 1 |
| tigecycline Drug Profile | 386 | 1 |
| tosedostat Drug Profile | 387 | 5 |
| triciribine phosphate Drug Profile | 392 | 3 |
| ulocuplumab Drug Profile | 395 | 1 |
| vadastuximab talirine Drug Profile | 396 | 4 |
| venetoclax Drug Profile | 400 | 9 |
| vorinostat Drug Profile | 409 | 4 |
| vosaroxin Drug Profile | 413 | 12 |
| Relapsed Acute Myeloid Leukemia Dormant Projects | 425 | 2 |
| Relapsed Acute Myeloid Leukemia Discontinued Products | 427 | 1 |
| Relapsed Acute Myeloid Leukemia Product Development Milestones | 428 | 13 |
| Featured News &Press Releases | 428 | 1 |
| Oct 18, 2016: Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Iomab-B | 428 | 1 |
| Oct 13, 2016: Sunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin | 428 | 1 |
| Sep 19, 2016: Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia | 428 | 1 |
| Sep 08, 2016: BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference | 429 | 1 |
| Aug 09, 2016: Actinium Pharmaceuticals Granted SME Status by the European Medicines Agency; Reiterates Focus on EU Market | 430 | 1 |
| Jul 20, 2016: Actinium Pharmaceuticals Highlights Successful Investigator Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial | 431 | 1 |
| Jul 12, 2016: ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia | 432 | 1 |
| Jul 06, 2016: Actinium Pharmaceuticals to Sponsor Investigator Meeting for Pivotal Phase 3 SIERRA Trial for Iomab-B | 433 | 1 |
| Jun 29, 2016: Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA Trial | 434 | 2 |
| Jun 13, 2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1 | 436 | 1 |
| Jun 13, 2016: Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD Anderson Sponsored Trial in Frontline Elderly AML and MDS at the EHA Annual Meeting | 436 | 1 |
| Jun 10, 2016: GlycoMimetics GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML | 437 | 1 |
| Jun 09, 2016: Actinium Announces Strong Presence at Society of Nuclear Medicine and Molecular Imaging Annual Meeting | 438 | 1 |
| Jun 06, 2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress | 439 | 1 |
| Jun 06, 2016: GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia | 439 | 2 |
| Appendix | 441 | 2 |
| Methodology | 441 | 1 |
| Coverage | 441 | 1 |
| Secondary Research | 441 | 1 |
| Primary Research | 441 | 1 |
| Expert Panel Validation | 441 | 1 |
| Contact Us | 441 | 1 |
| Disclaimer | 442 | 1 |